MENU
HELX
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
HELX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HELX with price predictions
Aug 14, 2026

HELX in -2.17% downward trend, falling for three consecutive days on August 14, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HELX declined for three days, in of 280 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HELX moved out of overbought territory on August 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

HELX broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on HELX as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HELX just turned positive on August 07, 2026. Looking at past instances where HELX's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NYSE:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Guardant Health (NASDAQ:GH), Exact Sciences Corp (NASDAQ:EXAS), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 42.08B. The market cap for tickers in the group ranges from 199.03M to 1.05T. LLY holds the highest valuation in this group at 1.05T. The lowest valued company is VYGR at 199.03M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was -1%. For the same ETF, the average monthly price growth was 4%, and the average quarterly price growth was 19%. FDMT experienced the highest price growth at 31%, while WVE experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was -53%. For the same stocks of the ETF, the average monthly volume growth was -24% and the average quarterly volume growth was -58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 63
Price Growth Rating: 41
SMR Rating: 77
Profit Risk Rating: 79
Seasonality Score: -8 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com